Bacteria-Derived Outer-Membrane Vesicles Hitchhike Neutrophils to Enhance Ischemic Stroke Therapy

Adv Mater. 2023 Sep;35(38):e2301779. doi: 10.1002/adma.202301779. Epub 2023 Jul 27.

Abstract

The treatment of reperfusion injury after ischemic stroke remains unsatisfactory since the blood-brain barrier (BBB) prevents most neuroprotective agents from entering the brain. Here, a strategy is proposed based on bacteria-derived outer-membrane vesicle (OMV) hitchhiking on the neutrophils for enhanced brain delivery of pioglitazone (PGZ) to treat ischemic stroke. By encapsulating PGZ into OMV, the resulting OMV@PGZ nanoparticles inherit the functions associated with the bacterial outer membrane, making them ideal decoys for neutrophil uptake. The results show that OMV@PGZ simultaneously inhibits the activation of nucleotide oligomerization-like receptor protein 3 (NLRP3) inflammasomes and ferroptosis and reduces the reperfusion injury to exert a neuroprotective effect. Notably, the transcription factors Pou2f1 and Nrf1 of oligodendrocytes are identified for the first time to be involved in this process and promoted neural repair by single-nucleus RNA sequencing (snRNA-seq).

Keywords: bacteria-derived outer-membrane vesicles; blood-brain barrier; ischemic stroke; nano-delivery systems; snRNA-seq.

MeSH terms

  • Bacteria
  • Extracellular Vesicles* / metabolism
  • Humans
  • Ischemic Stroke* / drug therapy
  • Ischemic Stroke* / metabolism
  • Neutrophils
  • Pioglitazone / metabolism
  • Reperfusion Injury* / metabolism

Substances

  • Pioglitazone